about
The thrombotic microangiopathy Registry of North America: A United States multi-institutional TMA network.Human neutrophil peptides and complement factor Bb in pathogenesis of acquired thrombotic thrombocytopenic purpuraReport of the ASFA apheresis registry study on Wilson's disease.Update on massive transfusion.How we approach a patient with symptoms of leukostasis requiring emergent leukocytapheresis.ADAMTS13 test and/or PLASMIC clinical score in management of acquired thrombotic thrombocytopenic purpura: a cost-effective analysis.An update on ABO incompatible hematopoietic progenitor cell transplantation.Report of the ASFA apheresis registry on muscle specific kinase antibody positive myasthenia gravis.New apheresis indications in hematological disorders.Use of hydroxyethyl starch in leukocytapheresis procedures does not increase renal toxicity.Apheresis research-more abstracts should be published as full manuscripts to provide more evidence for clinical practice guidelines.Mathematical model and calculation to predict the effect of prophylactic plasma transfusion on change in international normalized ratio in critically ill patients with coagulopathy.Retrospective analysis of community hospital red blood cell recovery procedures: improved utilization needed for effectiveness.A possible case of a haemolytic transfusion reaction caused by anti-Le(a) antibody.Acquired autoimmune thrombotic thrombocytopenic purpura in a case of severe haemophilia A.Adding neonatal hyperbilirubinemia/bilirubin encephalopathy to the American Society for Apheresis Guidelines on Therapeutic Apheresis.Anti-Blood Group Antibodies in Intravenous Immunoglobulin May Complicate Interpretation of Antibody Titers in ABO-Incompatible Transplantation.Hospital-acquired anemia due to diagnostic and therapy-related blood loss in inpatients with myasthenia gravis receiving therapeutic plasma exchange.Blood prime for patients with single-needle access requiring extracorporeal photopheresis: How to do and why it may be useful.Do we have enough evidence for recommending therapeutic plasma exchange for patients with natalizumab-associated progressive multifocal leukoencephalopathy?High Percentage of Evanescent Red Cell Antibodies in Patients with Sickle Cell Disease Highlights Need for a National Antibody Database.Phenotypically matched vs. traditional screen method for preparing red blood cell units in patients with abnormal placentation: a decision analysis approach.Recombinant activated factor VII in patients with acute liver failure with UNOS Status 1A: a single tertiary academic centre experience.Therapeutic plasma exchange for the treatment of anti-NMDA receptor encephalitis.Cost-Effectiveness Analysis of Plasma Versus Recombinant Factor VIIa for Placing Intracranial Pressure Monitors in Pretransplant Patients With Acute Liver Failure.Cryoprecipitate AHF vs. fibrinogen concentrates for fibrinogen replacement in acquired bleeding patients - an economic evaluation.Therapeutic plasma exchange for intractable pruritus secondary to primary sclerosing cholangitisRhesus Immune Globulin Dosing in the Obesity Epidemic EraTherapeutic plasma exchange in a patient with erythropoietic protoporphyria status post orthothopic liver transplantation as a bridge to hematopoietic stem cell transplantationThe use of plerixafor in hematopoietic progenitor cell collection in pediatric patients: a single center experienceGranulocyte transfusion therapy in pediatric patients after hematopoietic stem cell transplantation: a 5-year single tertiary care center experienceTherapeutic plasma exchange in two patients with stiff-person syndromePlasma vs. cryoprecipitate for fibrinogen replacement in therapeutic plasma exchange procedures"Black cloud" vs. "white cloud" physicians - Myth or reality in apheresis medicine?Exclusive use of PowerFlow ports may not be appropriate for all patientsNew subcutaneous PowerFlow port results in cost and time-savings in a busy outpatient apheresis clinicPotential impact of a delayed ADAMTS13 result in the treatment of thrombotic microangiopathy: an economic analysisAnti-Rh alloimmunization after trauma resuscitationN-Methyl-d-aspartate Receptor Antibody Encephalitis: A Concise Review of the Disorder, Diagnosis, and ManagementMonitoring Fondaparinux in the Setting of Antithrombin Deficiency
P50
Q33427586-2DDE348B-87DA-4299-877F-91482CC7A517Q33435545-D0CC9B88-3275-4BC9-B533-45E2A99EDEA7Q36463896-C5EA7D85-605E-4D26-BEC1-65E87F1246E3Q38171047-22EF7E6F-C610-4553-BEE0-9105BBC2A82EQ38565438-EA01A14B-E129-4811-BD2A-1E1245275A9EQ38711023-155CE011-A7B6-47B2-BBEC-E0B1EF4499FEQ38841289-0488297F-8296-464F-9BAC-5D5C36E08A06Q38899380-ADD67130-7100-4657-8ECF-98A661DBAF99Q38926108-537AF9E6-E4BB-4059-8000-2BF938B78AACQ38947834-3691DE83-6853-4B56-9862-165655F53DE7Q39002528-050C9368-0F99-4644-8F07-D3B14A621B52Q40157879-2C6FC94D-7436-4D95-AE13-AAB201C6CE90Q40267910-EA77E6CA-66F1-41DE-920F-2990AA58F4E6Q43207952-863D15DF-BBE1-4D11-BD0C-A1B231EF6B21Q45858905-704E7AAB-CBE6-40C8-8645-E1B95131CE46Q46376306-24B69EAF-D1CB-4FAA-931D-E08D0C2377A3Q48230185-9B3900CE-46A7-407E-9A4C-CC5DB2768845Q48337090-BA337CEB-8CF0-4DC2-BEFC-84D00551D552Q48338151-76F08A1C-27F6-4EFD-BC23-E612DF4202A3Q49990196-B704EB99-97A6-412A-83C8-CF04C0096A63Q50229388-06EB3269-9165-4570-9872-E3EA8EC5F02EQ50465216-CBE37EA7-0814-4ABF-BE4E-6605992F1B32Q50866803-30690733-4758-4321-9351-24CEECEBA101Q51010206-90B264DC-63F0-4CE2-956C-0A95D276164BQ51101241-D729941B-B76E-41BE-AB11-1C25AA18CBC3Q51726548-9408192B-CD7F-4BFC-A8DB-2423CDA2B005Q56794815-01FD94B8-2F0F-4421-940B-F807C08FFED6Q56794822-44B012C9-AA16-435C-9650-C748DD7968BBQ60627406-B7AE75D7-4882-4B85-B777-120200CFC7B0Q83459883-6834619F-1E23-43D8-BC74-9A9824E5B4DDQ84713886-57894F42-B9A5-4D07-8599-6388B363D134Q86268203-23C9A343-70F2-4B0D-815D-91B7D98E4AF7Q86959165-E9FA0093-E225-470D-83A1-C3B93EDC5E06Q88141376-5A00379E-15C0-4299-AD32-F322134DFA1EQ90161802-D9E02C53-C339-4BA1-B0F0-A7BA3F4300E7Q90479708-C8A00FC8-BF18-4C4A-864B-73E8093C3C6FQ90752855-71492F5B-7D54-4D29-9B63-B903F89C10F3Q91042377-B7092FCE-9CC7-4F9A-A9B6-3F3E3FE8807BQ91084403-336F07A5-C73B-4E67-BDFF-3081B9E5DDCCQ91250017-032BE125-5A37-4B34-93E3-15A0924448B8
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Huy P. Pham
@ast
Huy P. Pham
@en
Huy P. Pham
@es
Huy P. Pham
@nl
Huy P. Pham
@sl
type
label
Huy P. Pham
@ast
Huy P. Pham
@en
Huy P. Pham
@es
Huy P. Pham
@nl
Huy P. Pham
@sl
prefLabel
Huy P. Pham
@ast
Huy P. Pham
@en
Huy P. Pham
@es
Huy P. Pham
@nl
Huy P. Pham
@sl
P106
P1153
49662031500
P31
P496
0000-0003-4168-3859